Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: DTselentis who wrote (2701)	9/17/1999 8:55:00 AM
From: Art Bechhoefer	Read Replies (1) \| Respond to of 4676

I have a colleague in the Washington, DC area, who does consulting work evaluating the studies done for drug approval. She has reviewed several studies, including those involving antisense technology. Her opinion, on which I have based some of my investment decisions, is that antisense seems to be one of the more promising technologies. She is extremely conservative in her handling of statistical studies, so I take her opinion to be very positive. I look at the collaboration with Abbott Labs as a way to generate postive cash flow for ISIS. But the real value for ISIS should come from any one of the cancer drugs being tested, if the tests are successful.